Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
172
Completed, industry sponsors, Endocrinology and women's health, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed172
172 trials
Showing 1 to 25, recently updated first.
Corium Innovations, Inc.Industry
NCT07851649 · 68 participants · Start Jul 1, 2026 · Primary completion Sep 29, 2026
Drug: Test Estradiol/Levonorgestrel Transdermal Delivery System; Climara Pro® (Estradiol/Levonorgestrel Transdermal System) · For: Healthy Female Participants; Postmenopause
Sites: Ahmedabad, India
Crinetics Pharmaceuticals Inc.Industry
NCT05804669 · 19 participants · Start Oct 12, 2023 · Primary completion Aug 25, 2026
Drug: atumelnant · For: Cushing Syndrome; Cushing Disease; Ectopic ACTH Syndrome
Sites: Bethesda, Maryland
Triastek (Shanghai) LimitedIndustry
NCT07663318 · 18 participants · Start Jun 25, 2026 · Primary completion Jul 22, 2026
Drug: T25-Fast; Mycapssa and 1 more · For: Acromegaly
Sites: Zibo, China
Rovi Pharmaceuticals LaboratoriesIndustry
NCT06315205 · 84 participants · Start Jul 26, 2023 · Primary completion Mar 11, 2026
Drug: Letrozole LEBE 75 mg; Letrozole LEBE 150 mg and 1 more · For: Healthy
Sites: Prague, Czechia
Zi Diligence BiocenterIndustry
NCT07495007 · 26 participants · Start Nov 10, 2025 · Primary completion Dec 28, 2025
Drug: Progesterone IM of 100 mg; Progesterone IM of 100 mg · For: Bioequivalance; Post-menopause
Sites: Cairo, Egypt
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06513104 · 47 participants · Start Jul 18, 2024 · Primary completion Sep 10, 2025
Drug: NNC0519-0130; Levonorgestrel + Ethinylestradiol and 1 more · For: Diabetes Mellitus, Type 2
Sites: Berlin, Germany
Amneal Pharmaceuticals, LLCIndustry
NCT06467201 · 18 participants · Start Jun 3, 2024 · Primary completion Dec 8, 2024
Drug: KSHN001126 150mg; KSHN001126 300mg and 1 more · For: Healthy Postmenopausal Women
Sites: Miami, Florida; Ahmedabad, India
Entera Bio Ltd.Industry
NCT05965167 · 45 participants · Start May 11, 2023 · Primary completion Feb 8, 2026
Drug: EBP05; Forteo 0.02 mg and 6 more · For: Hypoparathyroidism; Osteoporosis; Fractures, Bone and 1 more
Sites: Jerusalem, Israel
Eli Lilly and CompanyEli Lilly (LLY)
NCT04647487 · 87 participants · Start Apr 21, 2021 · Primary completion Nov 11, 2022
Drug: LY3484356 · For: Breast Cancer
Sites: Atlanta, Georgia; Chicago, Illinois; Boston, Massachusetts · 19 sites in all
SanofiSanofi (SNY)
NCT04940026 · 6 participants · Start Jun 15, 2021 · Primary completion Aug 19, 2021
Drug: amcenestrant; [14C]-SAR439859 microtracer and 1 more · For: Breast Cancer; Healthy Volunteers
Sites: Nottingham, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06949124 · 20 participants · Start Apr 28, 2025 · Primary completion Jun 5, 2025
Drug: SHR7280 Tablets · For: Endometriosis; Uterine Fibroids; Assisted Reproduction
Sites: Wuhan, China
AstraZenecaAstraZeneca (AZN)
NCT06547164 · 40 participants · Start Aug 27, 2024 · Primary completion Aug 20, 2025
Drug: Midazolam; Camizestrant and 1 more · For: Healthy Participants
Sites: Harrow, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06969664 · 16 participants · Start May 19, 2025 · Primary completion Jul 5, 2025
Drug: SHR7280 Tablet; SHR7280 Placebo Tablet · For: Endometriosis; Uterine Fibroids; Assisted Reproduction
Sites: Guangzhou, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06797505 · 87 participants · Start Feb 10, 2025 · Primary completion Apr 29, 2025
Drug: PEG-rhGH with new preparation (T); PEG-rhGH with present preparation (T) · For: Pediatric Growth Hormone Deficiency (PGHD)
Sites: Chengdu, China
QuadMedicineIndustry
NCT06644040 · 24 participants · Start Oct 25, 2024 · Primary completion Dec 30, 2024
Drug: TeriQ Patch; Teribone Inj. and 1 more · For: Osteoporosis
Sites: Joondalup, Australia; Nedlands, Australia
Immunwork, Inc.Industry
NCT06372652 · 32 participants · Start Jun 18, 2024 · Primary completion Oct 10, 2024
Drug: TE-8214 - SAD; Placebo · For: Acromegaly
Sites: Adelaide, Australia
- A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different PreparationsCompleted
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06135168 · 60 participants · Start Oct 31, 2023 · Primary completion Nov 29, 2023
Drug: PEG-rhGH with new preparation; PEG-rhGH with present preparation · For: Pediatric Growth Hormone Deficiency (PGHD)
Sites: Chengdu, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06385145 · 16 participants · Start May 8, 2024 · Primary completion Jul 5, 2024
Drug: PEG-rhGH with new preparation (T); PEG-rhGH with present preparation (R) · For: Pediatric Growth Hormone Deficiency (PGHD)
Sites: Chengdu, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06135155 · 48 participants · Start Nov 6, 2023 · Primary completion Dec 4, 2023
Drug: PEG-rhGH with new preparation; PEG-rhGH with present preparation · For: Pediatric Growth Hormone Deficiency (PGHD)
Sites: Chengdu, China
AstraZenecaAstraZeneca (AZN)
NCT05790304 · 22 participants · Start Feb 20, 2023 · Primary completion Feb 22, 2024
Drug: Camizestrant · For: Hepatic Impairment
Sites: San Antonio, Texas; Sofia, Bulgaria; Bratislava, Slovakia · 4 sites in all
BayerBayer (BAYRY)
NCT02865538 · 76 participants · Start Aug 1, 2016 · Primary completion Mar 28, 2017
Drug: BAY3427080; Placebo (for BAY3427080) · For: Post-menopausal Vasomotor Symptoms
Sites: DeLand, Florida; Miami, Florida; San Antonio, Texas
Rovi Pharmaceuticals LaboratoriesIndustry
NCT03401320 · 53 participants · Start Nov 6, 2017 · Primary completion May 17, 2024
Drug: Letrozole ISM · For: Healthy
Sites: Prague, Czechia
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06331026 · 87 participants · Start Apr 9, 2024 · Primary completion Jul 15, 2024
Drug: PEG-rhGH with new preparation (T); PEG-rhGH with present preparation (R) · For: Pediatric Growth Hormone Deficiency (PGHD)
Sites: Chengdu, China
- A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female ParticipantsCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT04277624 · 22 participants · Start Feb 20, 2020 · Primary completion Feb 21, 2021
Drug: fezolinetant - test formulation; fezolinetant - reference formulation · For: Healthy Volunteers
Sites: Baltimore, Maryland
Astellas Pharma IncAstellas (ALPMY)
NCT03436849 · 44 participants · Start Feb 22, 2018 · Primary completion May 23, 2018
Drug: ESN364; Placebo · For: Healthy Subjects
Sites: Fukuoka, Japan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.